LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SMMT
Summit Therapeutics Inc.
There isn't enough reported data to score SMMT yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SMMT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SMMT's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SMMT PE Valuation
SMMT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SMMT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect SMMT's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SMMT on earnings quality, reporting a profit while its opponent remains loss making.
SMMT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.06 | +$0.18 |
| Q2 2026 | -$1.11 | -$0.10 |
| Q1 2026 | -$1.59 | -$1.25 |
| Q4 2025 | -$1.44 | -$1.13 |
| Q3 2025 | -$1.24 | -$0.96 |
| Q2 2025 | -$1.01 | -$0.78 |
| Q1 2025 | -$0.34 | -$0.18 |
| Q4 2024 | -$0.31 | +$1.22 |
SMMT lost $1.06 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
SMMT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $220K | -83% |
| Q2 2022 | $235K | +312% |
| Q1 2022 | $250K | +30% |
| Q4 2021 | $251K | +36% |
| Q3 2021 | $1.3M | +623% |
SMMT's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -7700% | -6211 points |
| Q2 2022 | -5401% | +36231 points |
| Q1 2022 | -8863% | -49 points |
| Q4 2021 | -10377% | -3054 points |
| Q3 2021 | -1489% | +8576 points |
| Q2 2021 | -41632% | N/A |
| Q1 2021 | -8814% | N/A |
| Q4 2020 | -7324% | N/A |
SMMT's operating margin was −7700% last quarter, down 6211 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SMMT on cash generation, producing positive trailing cash flow while its opponent burns cash.
SMMT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$160.2M | -$67.1M |
| Q2 2026 | -$142M | -$75.3M |
| Q1 2026 | -$122.5M | -$60.9M |
| Q4 2025 | -$102.1M | -$53.4M |
| Q3 2025 | -$93.2M | -$62.8M |
| Q2 2025 | -$66.7M | -$33.7M |
| Q1 2025 | -$61.6M | -$31.5M |
| Q4 2024 | -$48.7M | -$29.2M |
SMMT has burned cash in almost every quarter: −$527M over the past year, against −$270M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SMMT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SMMT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.6% | +20M shares |
| 1 year | +7.4% | +54.8M shares |
| 3 years | +14% | +100M shares |
| 5 years | +781% | +708M shares |
SMMT has 798M diluted shares, up 7.4% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SMMT Net Leverage
SMMT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SMMT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.2 | Neutral |
| Stochastic | 53.3 | Neutral |
SMMT's weekly RSI is 47 (neutral) and its Stochastic is 53 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SMMT PE vs Healthcare Sector
SMMT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SMMT on trend strength, trading above more of its moving averages.
SMMT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.9 | 5.5% below |
| 20 week MA | $15.3 | 1.4% below |
| 50 week MA | $16.3 | 7.8% below |
| 100 week MA | $19.0 | 21% below |
| 200 week MA | $12.6 | 19% above |
SMMT has fallen below most of its moving averages, though it's still 19% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SMMT on returns for 2026, with the stronger performance.
SMMT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.55 | $5.70 | +268% |
| 2021 | $5.70 | $3.03 | -47% |
| 2022 | $3.03 | $3.67 | +21% |
| 2023 | $3.67 | $2.61 | -29% |
| 2024 | $2.61 | $18.2 | +598% |
| 2025 | $18.2 | $18.1 | -0.4% |
| 2026 YTD | $18.1 | $15.1 | -17% |
SMMT's yearly returns have swung widely, from +598% in 2024 to −47% in 2021. It's down 17% so far in 2026.